This was consistent with the analysis of CLL and AML patients that relapsed on venetoclax therapy, as well as with other published studies seeking to identify resistance factors to BCL-2 inhibitors [22, 23, 25–29]. Here, BCL2 is linked to acute myeloid leukemia.